Supernus Pharmaceuticals, a biopharmaceutical company specializing in treatments for central nervous system diseases, will announce its third quarter 2026 financial results after market close on October 29, 2026. The company's President and CEO, Jack Khattar, along with CFO Tim Dec, will hold a conference call and webcast at 4:30 p.m. ET the same day to discuss the results and answer questions. Investors can access the live webcast through the company's investor relations website, with a replay available for 60 days. This update is important as it provides insight into the company's financial health and progress in developing CNS disorder treatments.
Supernus Pharmaceuticals is set to announce its Q3 2026 financial results on October 29, 2026. For readers following the health sector, here is Pluang's market snapshot as of Oct 19, 2026 18:43 WIB: out of 150 priced health-sector US stocks, 68 rose and 54 fell. Notable movers include Revolution Medicines Inc. (RVMD) at USD 181.96 with a 1-day change of +2.25%, Arrowhead Pharmaceuticals Inc. (ARWR) at USD 56.94 with +1.86%, and Twist Bioscience Corp (TWST) at USD 135.06 with +1.74%.
Bill Gross, a serial entrepreneur behind over 175 companies, has launched Idealab.ai, a platform using AI to generate and share over 1.2 million business ideas based on real-world problems. The platform aims to lower barriers to entrepreneurship by h...
The Portnoy Law Firm has launched an investigation into Cardinal Infrastructure Group for possible securities fraud following the company's Q2 2026 financial report. Cardinal revealed a decline in its gross profit margin to 10.8%, down from 13.9% the...
AIOS Tech Inc. announced an agreement to acquire SmartCore Holdings Limited in an all-stock transaction valued at approximately $100 million. The deal will issue 33.3 million AIOS shares to SmartCore's sellers, who will hold about 80% of AIOS shares ...
XBiotech announced positive results from the Phase II TASKIN trial, where their antibody vilamakitug combined with standard chemotherapy improved 12-month overall survival to 61.3% in refractory metastatic colorectal cancer patients, surpassing the s...
Proof and Circle Internet Group demonstrated a new system where AI agents can prove the identity of the person they represent using Proof's x401 open identity protocol and pay merchants in USDC via Circle's x402 payment protocol. This innovation addr...
